Fireside Chat: Understanding the Lived Experience of IPF Directly from the Patient

As IPF drug development grows more complex, it’s important to pause and reflect on why we do what we do. This session brings the conversation back to what matters most, grounding scientific and clinical discussions in real patient impact, and ensuring progress across the field remains both meaningful and measurable.

Speakers:

Amy Case, MD, FCCP

CMO

Pulmonary Fibrosis Foundation